To the Editor:Co-reactivation of cytomegalovirus(CMV)and Epstein–Barr virus(EBV)is common after haploidentical stem cell transplantation(haplo-SCT)and can lead to potentially life-threatening complications.[1,2]Adopt...To the Editor:Co-reactivation of cytomegalovirus(CMV)and Epstein–Barr virus(EBV)is common after haploidentical stem cell transplantation(haplo-SCT)and can lead to potentially life-threatening complications.[1,2]Adoptive immunotherapy with virus-specific T lymphocytes(VSTs)is a critical treatment option that has shown promising results in controlling CMV and EBV infections in several clinical studies,providing protection for 70–90%of patients.[3]Multi-virus-specific T cell lines offer an advanced method for simultaneously addressing multiple challenging viral infections.However,data regarding its long-term efficacy are limited.Additionally,clinical trials with multi-virus-specific T cells have predominantly focused on single virus reactivation,leaving gaps in our understanding of the effectiveness of VSTs during multivirus co-reactivation.Antigenic competition may affect the expansion of virus-specific T cells in vitro during the generation of multi-virus-specific cell lines.Whether in vivo competition among infused cells compromises the efficacy of adoptively transferred VSTs remains unclear.展开更多
基金funded by the National Key Research and Development Program of China(No.2022YFA0103300)Being Nova Program(No.20220484076)+2 种基金Major Program of the National Natural Science Foundation of China(Nos.82070184 and 82293630)Beijing Municipal Science&Technology Commission(No.Z211100002921071)Peking University Clinical Scientist Training Program(No.BMU2024PYJH012).
文摘To the Editor:Co-reactivation of cytomegalovirus(CMV)and Epstein–Barr virus(EBV)is common after haploidentical stem cell transplantation(haplo-SCT)and can lead to potentially life-threatening complications.[1,2]Adoptive immunotherapy with virus-specific T lymphocytes(VSTs)is a critical treatment option that has shown promising results in controlling CMV and EBV infections in several clinical studies,providing protection for 70–90%of patients.[3]Multi-virus-specific T cell lines offer an advanced method for simultaneously addressing multiple challenging viral infections.However,data regarding its long-term efficacy are limited.Additionally,clinical trials with multi-virus-specific T cells have predominantly focused on single virus reactivation,leaving gaps in our understanding of the effectiveness of VSTs during multivirus co-reactivation.Antigenic competition may affect the expansion of virus-specific T cells in vitro during the generation of multi-virus-specific cell lines.Whether in vivo competition among infused cells compromises the efficacy of adoptively transferred VSTs remains unclear.
